1st TNF antagonist (417) | 2nd TNF antagonist (83) | 3rd TNF antagonist (18) | |
---|---|---|---|
Age, years (SD) | 53 ± 13 | 52 ± 12 | 44 ± 11 |
Gender (F) | 342 (82%) | 68(82%) | 17(94%) |
Disease duration years (SD) | 10.4 (± 8,2) | 10 (± 8) | 11(± 8) |
RF positive, % | 68% | 69% | 61% |
Radiographic erosions, % | 74% | 79% | 94% |
Concomitant DMARD, % | 94% | 94% | 100% |
Methotrexate | 78% | 71% | 50% |
Leflunomide | 8% | 2% | 17% |
Antimalarial | 5% | 4% | 5% |
Oral glucocorticoids, % | 83% | 83% | 51% |
Adalimumab, n | 38 | 36 | 12 |
Etanercept, n | 141 | 46 | 5 |
Infliximab, n | 238 | 1 | 1 |